PMC:7361216 / 5473-5622
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T69 | 14-22 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T33 | 0-149 | Sentence | denotes | Reductions in antibody were sustained for as long as 96 hr, demonstrating the pharmacologic feasibility of this highly specific therapeutic approach. |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T69 | 14-22 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T33 | 0-149 | Sentence | denotes | Reductions in antibody were sustained for as long as 96 hr, demonstrating the pharmacologic feasibility of this highly specific therapeutic approach. |